Tuesday, January 28, 2025 4:01:09 PM
bas2020,
Don’t let them get to you they just want to divide longs and create dissension. Several on the board have mentioned using your trading strategy to increase share count by trading around a core position or just mitigate risk. I have steadily accumulated over the years and really bought big between $.17 and $.22 after the double bottom was called on this board. When news hits those with NWBO shares will see immediate and then longer term price appreciation in my opinion. What happens after first news is almost always a price correction to baseline support of a newly established uptrend being created. Investor082 asserts the first part of the equation but not the second part which likely will get established within one week of price reaction to initial news either from speculation about partnerships or buyouts or because of other manufacturing and or reimbursement pathway news which are topics that the public will want to know about very quickly after any approval announcement. NWBO and NHS will both get the kind of attention they don’t want if something is not already worked out. This is pretty obvious which is why Investor082 keeps mentioning his expectation of significant price decline if NWBO does not handle this news differently by being prepared with more news right after or with it. Best wishes.
Don’t let them get to you they just want to divide longs and create dissension. Several on the board have mentioned using your trading strategy to increase share count by trading around a core position or just mitigate risk. I have steadily accumulated over the years and really bought big between $.17 and $.22 after the double bottom was called on this board. When news hits those with NWBO shares will see immediate and then longer term price appreciation in my opinion. What happens after first news is almost always a price correction to baseline support of a newly established uptrend being created. Investor082 asserts the first part of the equation but not the second part which likely will get established within one week of price reaction to initial news either from speculation about partnerships or buyouts or because of other manufacturing and or reimbursement pathway news which are topics that the public will want to know about very quickly after any approval announcement. NWBO and NHS will both get the kind of attention they don’t want if something is not already worked out. This is pretty obvious which is why Investor082 keeps mentioning his expectation of significant price decline if NWBO does not handle this news differently by being prepared with more news right after or with it. Best wishes.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
